MetaCap

GRI Bio (GRI) vs Mustang Bio (MBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mustang Bio is the larger company by market cap ($2.7 million vs $2.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRI-39.46%MBIO-21.35%
+5%-18%-42%
Oct 7, 20261 yearNov 20, 2026
GRI-35.63%MBIO-11.50%
+10%-14%-38%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRI versus MBIO key metrics
MetricGRIMBIO
Share price$1.12$0.3541
Market cap$2.45M$2.69M
1-day change0.00%-4.30%
P/E ratio (TTM)0.05—
EPS (TTM)$20.57$-0.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-11.96M$-1.92M
52-week high$64.12$1.43
52-week low$1.09$0.35
Distance from 52-week high-98.25%-75.24%
Analyst consensusnone—
Avg. price target upside+1551.79%—
Average volume218.31K33.87K
Shares outstanding2.19M6.74M
Employees34
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About GRI Bio

GRI stock →

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees

About Mustang Bio

MBIO stock →

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

GRI vs MBIO FAQ

Which is bigger, GRI Bio or Mustang Bio?

Mustang Bio (MBIO) is larger, with a market capitalization of $2.69M compared with $2.45M for GRI Bio (GRI).

Are GRI Bio and Mustang Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons